Trine-Lise Larsen

• Ikdahl, Eirik; Rollefstad, Silvia Christin Hellerud; Kazemi, Amirhossein; Provan, Sella Aarrestad; Larsen, Trine-Lise & Semb, Anne Grete (2023). Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 10(1), p. 27–34. doi: 10.1093/ehjcvp/pvad078. Full text in Research Archive Show summary

  Aims Patients with inflammatory joint diseases (IJD), including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have increased rates of pulmonary embolism (PE). Non-steroidal anti-inflammatory drugs (NSAIDs) use is associated with PE in the general population. Our aim was to evaluate the association between NSAIDs use and PE in IJD patients. Methods and results Using individual-level registry data from the whole Norwegian population, including data from the Norwegian Patient Registry and the Norwegian Prescription Database, we: (1) evaluated PE risk in IJD compared to non-IJD individuals, (2) applied the self-controlled case series method to evaluate if PE risks were associated with use of traditional NSAIDs (tNSAIDs) and selective cox-2 inhibitors (coxibs). After a one-year wash-out period, we followed 4 660 475 adults, including 74 001 with IJD (RA: 39 050, PsA: 20 803, and axSpA: 18 591) for a median of 9.0 years. Crude PE incidence rates per 1000 patient years were 2.02 in IJD and 1.01 in non-IJD individuals. Age and sex adjusted hazard ratios for PE events were 1.57 for IJD patients compared to non-IJD. Incidence rate ratios (IRR) [95% confidence interval (CI)] for PE during tNSAIDs use were 0.78 (0.64–0.94, P = 0.010) in IJD and 1.68 (1.61–1.76, P < 0.001) in non-IJD. IRR (95% CI) for PE during coxibs use was 1.75 (1.10–2.79, P = 0.018) in IJD and 2.80 (2.47–3.18, P < 0.001) for non-IJD. Conclusion Pulmonary embolism rates appeared to be higher in IJD than among non-IJD subjects in our study. Traditional NSAIDs may protect against PE in IJD patients, while coxibs may associated with increased PE risk.

• Hussaini, Parwana; Larsen, Trine-Lise; Ghanima, Waleed & Dahm, Anders Erik A (2023). Risk factors for bleeding in cancer patients treated with conventional dose followed by low-dose apixaban for venous thromboembolism. Thrombosis and Haemostasis. ISSN 0340-6245. doi: 10.1055/a-2188-8773.
• Larsen, Trine-Lise; Svalastoga, Marte; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Garresori, Herish [Show all 16 contributors for this article] (2023). Arterial events in cancer patients treated with apixaban for venous thrombosis. Thrombosis Research. ISSN 0049-3848. 228, p. 128–133. doi: 10.1016/j.thromres.2023.05.017.
• Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie [Show all 15 contributors for this article] (2022). Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 20(5), p. 1166–1181. doi: 10.1111/jth.15666. Full text in Research Archive Show summary

  Background There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban for 30 months, after initial 6 months of full-dose treatment. Methods We included 298 patients with cancer and any type of VTE in a single arm interventional clinical trial. All patients were treated with full-dose apixaban (5 mg twice daily) for 6 months. Total 196 patients with active cancer after 6 months treatment continued with apixaban 2.5 mg twice daily for another 30 months. The main endpoints were recurrent VTE, major bleeding and clinically relevant non-major bleeding. Results During the 30 months of treatment with low-dose apixaban 14 (7.6%; 95% confidence interval (CI) 4.0%–11.7%) patients experienced recurrent VTE, six (3.1%; 95% CI 1.1%–6.5%) experienced major bleeding and 16 (8.1%, 95% CI: 4.7%–12.8%) experienced clinically relevant non-major bleeding. The incidence rate per person month of recurrent VTE was 0.8% (95% CI 0.41–1.6) at 2–6 months with full-dose apixaban, and 1.0% (95% CI 0.5–1.9) at 7–12 months with low-dose apixaban. The incidence rate of major bleeding was 1.1% (95% CI 0.6–2.0) at 2–6 months, and 0.3% (95% CI 0.1–1.0) at 7–12 months. Between 12 and 36 months the incidence rate of recurrent VTE and major bleedings remained low. Conclusion Dose reduction of apixaban to 2.5 mg twice daily seems safe after 6 months of full-dose treatment. After 12 months the incidence rate of recurrent VTE and major bleeding remained low.

• Hannevik, Trine-Lise; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Ahmed, Herish & Jacobsen, Eva-Marie [Show all 15 contributors for this article] (2020). Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. Thrombosis Research. ISSN 0049-3848. 196, p. 238–244. doi: 10.1016/j.thromres.2020.08.042.

View all works in Cristin

• Larsen, Trine-Lise; Ghanima, Waleed; Sandset, Per Morten; Frøen, Hege; Jacobsen, Eva-Marie & Torfoss, Dag [Show all 7 contributors for this article] (2023). Faktor Xa-hemmere til forebygging og behandling av venøs tromboembolisme ved kreft. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(1). doi: 10.4045/tidsskr.22.0228. Full text in Research Archive
• Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie [Show all 15 contributors for this article] (2022). “Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up”: Reply. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 20(8), p. 1937–1939. doi: 10.1111/jth.15774.
• Dahm, Anders Erik Astrup & Hannevik, Trine-Lise (2019). Forebygging av venøs tromboembolisme ved kreft - hvilke pasienter kan DOAK være relevante for? . BestPractice Nordic. ISSN 1902-7583.

View all works in Cristin